An interventional study of Non-adaptive reminder text messaging and Adaptive interventions in Antiretroviral Therapy (ART) Adherence Among Adolescents Living With HIV, sponsored by Arba Minch University. Not yet recruiting at 1 site in Ethiopia. Open to participants aged 15 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Arba Minch University · Not applicable, Interventional, and Treatment
Many adolescents living with HIV have difficulty taking their medicine on time, which can make it less effective and affect their health. This study will test whether sending reminder text messages, combined with small rewards like school supplies, hygiene kits, or sports items, can help adolescents take their HIV medicine regularly and stay in care. Each adolescent will choose a daily habit or routine to link to their medication. We will compare two groups receiving messages and rewards to a group receiving standard care to see which approach works best. We will also ask participants about their experience with the messages and rewards. The aim is to find a simple and effective way to help adolescents living with HIV stay healthy and in care.
Arba Minch University is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Adaptive interventions · Behavioral: The control arm
Behavioral: Non-adaptive reminder text messaging · Behavioral: The control arm
Non-adaptive reminder text messaging combined with non-monetary incentives versus the standard of care. Under this sub-aim, we will compare adherence levels between those who receive continuous text messaging combined with participant-preferences of daily cue and medication time.
Participants will choose a lifestyle 'cue,' as in arm 1, and receive daily, personalized text message reminders tailored to their selected cues for the first three months. After three months, adherence will be evaluated, and a non-monetary reward will be provided to both adherent and non-adherent participants. Following this, the cue reminder text messages will be discontinued for participants who achieved 95% ART adherence over the next 12-month period. However, they will receive a non-monetary reward for achieving 95% ART adherence over six months of follow-up.
In the control arm, all adolescents will receive the standard care as per the national guidelines (25). The standard care provided encompasses counseling, mental health support, nutritional assessment, and social and emotional support given by family, friends, and healthcare providers to adolescents diagnosed with HIV.
Adaptive text messaging reminders combined with non-monetary incentives to improve sustained adherence to antiretroviral treatment among adolescents in Ethiopia: a hybrid effectiveness-implementation trial
ART adherence will be measured using a multi-method composite adherence assessment tool based on previously validated measures, including self-reported adherence, pill count (PC), and retention in care (missed appointments). Self-reported adherence will be assessed through four validated yes/no questions addressing difficulties remembering medication, intentional discontinuation when feeling better or worse, and missed doses over the preceding four days. Participants will also rate their adherence over the past 30 days using a visual analogue scale (VAS) ranging from 0 (no adherence) to 10 (perfect adherence). Each adherence component will be dichotomized using established thresholds (≥95% adherence for self-report, pill count, and VAS; no missed appointments for retention in care) and assigned a score of 1 (adherent) or 0 (non-adherent). Component scores will be summed to generate a composite adherence index ranging from 0 to 3, which will be reported as a single adherence measure ca
Time frame: 12 months
Implementation Outcomes of Adaptive SMS Reminders with Incentives for Adolescents Living with HIV
Implementation Outcomes: The delivery, uptake, and integration of the adaptive SMS reminder and non-monetary incentive intervention will be evaluated by assessing six key implementation outcomes: acceptability, feasibility, fidelity, adoption/uptake, penetration/reach, and sustainability/maintenance. Description of Outcome Measures: Acceptability: Measured using the validated Acceptability of Intervention Measure (AIM) and supplemented with in-depth qualitative interviews with participants regarding the intervention's content, timing, and incentives. Assessment timepoints: 3, 6, 9, and 12 months. Feasibility: Evaluated through digital logs of SMS delivery, records of incentive distribution, and semi-structured interviews with clinic staff to identify barriers, facilitators, and ease of implementation. Formally assessed at 6 and 12 months, with continuous process monitoring. Fidelity: Assessed by comparing the planned intervention protocol
Time frame: 3-12 months
Effect of Adaptive SMS and Incentives on 12-Month Viral Suppression in Adolescents with HIV
The proportion of adolescents living with HIV who maintain a viral load below 1,000 copies/mL at the 12-month study visit, assessed as the primary clinical effectiveness outcome of the adaptive SMS and incentive intervention
Time frame: 12 months
Cost-Effectiveness and Cost-Utility of Adaptive SMS Reminders with Non-Monetary Incentives for Improving ART Adherence Among Adolescents with HIV
This study will perform a comprehensive economic evaluation from both healthcare system and societal perspectives. The analysis will compare the incremental costs and health outcomes of the combined adaptive SMS reminder and non-monetary incentive intervention against the standard of care. Cost-effectiveness will be assessed as the incremental cost per additional adolescent achieving sustained ART adherence. Cost-utility will be measured as the incremental cost per Quality-Adjusted Life Year (QALY) gained, with health utilities derived from the EQ-5D-Y/3L instrument administered at baseline, 6, and 12 months. We will calculate Incremental Cost-Effectiveness Ratios (ICERs) and conduct sensitivity analyses to assess uncertainty. A budget impact analysis will model the financial consequences of potential scale-up.
Time frame: 12 months
Patient-Level Psychosocial and Behavioral Determinants of ART Adherence
This study will measure a comprehensive set of patient-level factors hypothesized to influence sustained adherence to antiretroviral therapy (ART) among adolescents living with HIV. Validated self-report scales will be used to assess habit strength, intrinsic motivation, HIV-related stigma, depressive symptoms, and perceived social support. Rationale for Measurement Schedule: Baseline: To establish initial levels, identify baseline predictors of subsequent adherence and viral load suppression/rebound, and allow for statistical adjustment of participant differences. 3-Month Follow-up: To detect initial changes in psychosocial factors and investigate early mediators of adherence behavior following intervention initiation. 6-Month Follow-up (Midline): To track short-term trends and identify adaptation or emerging challenges in adherence behavior. 9- and 12-Month Follow-ups: To assess the longer-term trajector
Time frame: Measurement Time Points: Baseline, 3, 6, 9, and 12 months post-enrollment.
Patient-Level Determinants and Contextual Factors
Patient-level determinants, including habit strength, intrinsic motivation, HIV-related stigma, depressive symptoms, and social support, will be measured using validated self-report scales at baseline, 3, 6, 9, and 12 months. Baseline: Establish initial levels, identify predictors of adherence and viral suppression and its rebound, and allow adjustment for participant differences. Early follow-up (3 months): Detect initial changes and early mediators of adherence. Midline (6 months): Track short-term trends, adaptation, and challenges in adherence behavior. Later follow-ups (9 and 12 months): Assess longer-term changes and maintenance of psychosocial factors. These measures will be analyzed as potential mediators or moderators of sustained ART adherence and viral load suppression.
Time frame: From baseline to 12-months
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.